Xoma Shares Rally Following Strategic Biotech Acquisition
Published on 11/24/2025 at 18:21 | Redaktion boerse-global.de
Xoma Royalty shares demonstrated positive momentum at the week’s opening, trading at $32.14 and marking a nearly 1 percent gain. This upward movement follows the company’s successful acquisition of LAVA Therapeutics, a strategic move that significantly enhances its portfolio. The transaction brings economic interests in two promising cancer therapeutics, developed in collaboration with industry leaders Johnson & Johnson and Pfizer.
Finalized on November 21, the acquisition agreement stipulates that LAVA Therapeutics shareholders will receive $1.04 per share. Additionally, they will obtain a non-transferable Contingent Value Right (CVR). These CVRs entitle holders to 75% of the net proceeds generated from LAVA’s existing partner-related business and its company-controlled programs. A potential extra payment of up Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
